UPDATED: Interim Clinical Considerations for Use of COVID-19 Vaccines
Maine Department of Health & Human Services sent this bulletin at 05/09/2023 10:12 AM EDT
To: Maine Immunization Program Providers
From: Maine Immunization Program
Subject: UPDATED: Interim Clinical Considerations for Use of COVID-19 Vaccines
Date: May 9, 2023
**Interim Clinical Considerations for Use of COVID-19 Vaccines was recently updated to reflect changes as of May 5, 2023. **
The Maine Immunization Program sent out a notice to providers on April 18, 2023, informing them of the FDA authorization to amend the EUAs of the Moderna and Pfizer-BioNTech COVID-19 bivalent mRNA vaccines. This amendment simplifies the vaccination schedule for most individuals and authorizes the current bivalent vaccines to be used for all doses administered to individuals 6 months of age and older, including for an additional dose or doses for certain populations.
With an increase in calls from MIP providers, we would like to highlight the new recommendations in the charts below:
Ages 6 months–4 years
Age 5 years
Ages 6–11 years
Ages 12 years and older
Abbreviation: NA = not authorized
*An 8-week interval between the first and second doses of Moderna and Pfizer-BioNTech COVID-19 vaccines might be optimal for some people ages 6 months–64 years, especially for males ages 12–39 years, as it might reduce the small risk of myocarditis and pericarditis associated with these vaccines.
†FDA EUA requires that children who transition from age 4 years to 5 years during the Pfizer-BioNTech vaccination series receive the 0.2 mL/3 ug dosage (maroon cap and label with a maroon border) for all doses.
‡Children who transition from age 5 years to 6 years during the Moderna vaccination series should receive 2 doses of Moderna COVID-19 Vaccine (0.25 mL/25 ug; dark blue cap and label with a gray border).
